表紙
市場調查報告書

中國的人體疫苗產業:2020年-2026年

China Human Vaccine Industry Report, 2020-2026

出版商 ResearchInChina 商品編碼 951820
出版日期 內容資訊 英文 213 Pages
商品交期: 最快1-2個工作天內
價格
中國的人體疫苗產業:2020年-2026年 China Human Vaccine Industry Report, 2020-2026
出版日期: 2020年07月23日內容資訊: 英文 213 Pages
簡介

中國,2018年發生Changsheng Bio-Technology的冷凍乾燥狂犬病疫苗製造記錄偽造問題,人體疫苗的分批釋放減少了17.7%。由於此後對人體疫苗的管理嚴格化,此事件的影響逐漸消失。2019年,食品醫藥品審定研究院(NIFDC)承認與前一年比增加5.4%的5億7,000萬分的人類疫苗,白喉,破傷風,無細胞百日咳混合疫苗的分批釋放增加。

本報告提供中國的人體疫苗產業調查,市場和產業趨勢,主要製造商的簡介等資訊。

目錄

第1章 疫苗產業概要

  • 定義與分類
  • 產業鏈

第2章 中國的人體疫苗產業

  • 商業環境
    • 國際市場
    • 政策環境
    • 生物醫藥品市場
  • 現狀
  • 市場需求
  • 流通管道
  • 市場規模
  • 進出口
    • 進口
    • 出口
    • 平均價格
  • 競爭格局

第3章 市場區隔

  • B型肝炎疫苗
  • 腦膜炎疫苗
  • A型肝炎疫苗
  • 流感疫苗
  • Hib疫苗
  • 人用狂犬病疫苗
  • 水痘疫苗
  • 肺炎球菌疫苗
  • DTP疫苗
  • 小兒麻庳疫苗
  • E型肝炎疫苗
  • 人類乳突病毒(HPV)疫苗
  • 手足口病(HFMD)疫苗

第4章 主要企業的簡介

  • China National Biotech Group
  • Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
  • Hualan Biological Engineering Inc.
  • Chongqing Zhifei Biological Products Co., Ltd.
  • Walvax Biotechnology Co, Ltd.
  • Liaoning Cheng Da Co., Ltd.
  • Shenzhen Kangtai Biological Products Co., Ltd.
  • Changsheng Bio-Technology Co., Ltd.
  • Olymvax Biopharmaceuticals Inc.
  • Sinovac Biotech Ltd.
  • Changchun BCHT Biotechnology Co. Ltd.
  • Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
  • Tibet Amy Biotech & Vaccine Group Co., Ltd.
  • NCPC GeneTech Biotechnology Development Co., Ltd.
  • Dalian Aleph Biomedical Co., Ltd.
  • Beijing Minhai Biotechnology Co., Ltd.
  • CanSino Biologics
  • Chengdu Kanghua Biological Products Co., Ltd.

第5章 彙整與預測

  • 概要
  • 趨勢
目錄

In China, the lot release for human vaccines plunged by 17.7% in 2018 when the production record fraud of rabies vaccines for human use, freeze-dried by Changsheng Bio-Technology was exposed. The impact fades away amid tighter control on human vaccines in China. In 2019, National Institutes for Food and Drug Control (NIFDC) approved 570 million doses of human vaccine with a year-on-year increase of 5.4%, among which there was more lot release volume of diphtheria, tetanus and acellular pertussis combined vaccine (adsorbed), recombinant Hepatitis B vaccine, and rabies vaccine for human use (freeze-dried), together sharing 33.9% of the total.

The Chinese human vaccine market is now occupied by local companies, where the state-owned enterprises command more than a half of the market. In the first half of 2020, the players had more lot releases, such as China National Biotec Group (CNBG), Institute of Medical Biology, Chinese Academy of Medical Sciences, Walvax Biotechnology, Amy Biotech & Vaccine, Liaoning Cheng Da, NCPC GeneTech Biotechnology, and Sinovac Biotech, holding a combined 82.2% of the total. Noticeably, CNBG takes a lion's share 43.3%, leading the pack in the industry.

Although the Chinese human vaccine market is ruled by local companies, the imported vaccines are largely the extra EPI vaccines (not free, and residents can choose whether they want to be inoculated) such as 13-valent pneumonia vaccine, HPV vaccine and DTaP-IPV/Hib vaccine. Yet, the 13-valent pneumonia vaccine of Walvax Biotechnology and the 2-valent pneumonia vaccine of Xiamen Innovax Biotech are approved successively for general availability in the market, challenging the overseas vaccine giants at their games and scrambling for more market shares by price advantage, accompanied by the to-be-soon-launched vaccines like 13-valent pneumonia vaccine of Shenzhen Kangtai Biological Products Co., Ltd., 2-valent/9-valent HPV vaccines of Walvax Biotechnology, 4-valent influenza vaccine and 15-valent pneumonia vaccine of Chongqing Zhifei Biological Products Co., Ltd.

The devastating COVID-19 in more than 100 countries causes a total of over 14.77 million cases infected and approximately 609,000 deaths. The mortality rate is high up to 4.1% and the overriding research about coronavirus vaccine and clinical trials get under way.

In at least 200 coronavirus vaccine programs worldwide to date, China stays ahead temporarily in the R&D progress. Seven coronavirus vaccines are in the clinical phase, and Ad5-nCoV, an adenovirus vaccine being co-developed by CanSino Biologics, Inc. and the team led by the academician Chen Wei at the Biological Engineering Institute of Academy of Military Medical Sciences, is advancing faster as its phase-III clinical trials are in place. To curb the pandemic, the related authorities of China will accelerate the examination and approval process for a shorter development cycle and a faster launch to save lives.

Highlights of this report:

  • Human vaccine industry in China (environments, status quo, market demand, market size, import & export, competition pattern);
  • Human vaccine market segments in China (market demand, lot releases, competitive landscape);
  • 22 human vaccine companies (operation, vaccine business, etc.)
  • Conclusions and development tendencies

Table of Contents

1. Overview of Vaccine Industry

  • 1.1 Definition & Classification
  • 1.2 Industry Chain

2. China Human Vaccine Industry

  • 2.1 Operating Environment
    • 2.1.1 International Market
    • 2.1.2 Policy Environment
    • 2.1.3 Biopharmaceutical Market
  • 2.2 Status Quo
  • 2.3 Market Demand
  • 2.4 Circulation Channels
  • 2.5 Market Size
  • 2.6 Import & Export
    • 2.6.1 Import
    • 2.6.2 Export
    • 2.6.3 Average Price
  • 2.7 Competition Pattern

3. Human Vaccine Market Segments in China

  • 3.1 Hepatitis B Vaccine
    • 3.1.1 Demand
    • 3.1.2 Lot Release Volume
    • 3.1.3 Competition Pattern
  • 3.2 Meningococcal Vaccine
    • 3.2.1 Demand
    • 3.2.2 Lot Release Volume
    • 3.2.3 Competition Pattern
    • 3.2.4 Development Prospect
  • 3.3 Hepatitis A Vaccine
    • 3.3.1 Demand
    • 3.3.2 Lot Release Volume
    • 3.3.3 Competition Pattern
  • 3.4 Influenza Vaccine
    • 3.4.1 Demand
    • 3.4.2 Lot Release Volume
    • 3.4.3 Competition Pattern
    • 3.4.4 Development Trend
  • 3.5 Hib Vaccine
    • 3.5.1 Demand
    • 3.5.2 Lot Release Volume
    • 3.5.3 Competition Pattern
    • 3.5.4 Development Trend
  • 3.6 Human Rabies Vaccine
    • 3.6.1 Demand
    • 3.6.2 Lot Release Volume
    • 3.6.3 Competition Pattern
    • 3.6.4 Development Trend
  • 3.7 Varicella Vaccine
    • 3.7.1 Demand
    • 3.7.2 Lot Release Volume
    • 3.7.3 Competition Pattern
    • 3.7.4 Development Trend
  • 3.8 Pneumococcal Vaccines
    • 3.8.1 Demand
    • 3.8.2 Lot Release Volume
    • 3.8.3 Competition Pattern
    • 3.8.4 Development Trend
  • 3.9 DTP Vaccine
    • 3.9.1 Demand
    • 3.9.2 Lot Release Volume
    • 3.9.3 Competition Pattern
    • 3.9.4 Development Trend
  • 3.10 Poliomyelitis Vaccine
    • 3.10.1 Demand
    • 3.10.2 Lot Release Volume
    • 3.10.3 Competition Pattern
    • 3.10.4 Development Trend
  • 3.11 Hepatitis E Vaccine
    • 3.11.1 Demand
    • 3.11.2 Lot Release Volume
    • 3.11.3 Competition Pattern
  • 3.12 HPV Vaccine Has a Rosy Prospect and Is Expected to Be Localized
    • 3.12.1 Status Quo
    • 3.12.2 Lot Release Volume
    • 3.12.3 Competition Pattern
    • 3.12.4 Development Trend
  • 3.13 Hand, Foot and Mouth Disease (HFMD) Vaccine
    • 3.13.1 Demand
    • 3.13.2 Lot Release Volume
    • 3.13.3 Competition Pattern
    • 3.13.4 Development Trend

4. Major Human Vaccine Manufacturers in China

  • 4.1 China National Biotech Group
    • 4.1.1 Profile
    • 4.1.2 National Vaccine & Serum Institute
    • 4.1.3 Chengdu Institute of Biological Products Co., Ltd.
    • 4.1.4 Shanghai Institute of Biological Products Co., Ltd.
    • 4.1.5 Wuhan Institute of Biological Products Co., Ltd.
    • 4.1.6 Lanzhou Institute of Biological Products Co., Ltd.
    • 4.1.7 Changchun Institute of Biological Products Co., Ltd.
    • 4.1.8 Changchun Keygen Biological Products Co., Ltd.
  • 4.2 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
    • 4.2.1 Profile
    • 4.2.2 Operation
    • 4.2.3 Revenue Structure
    • 4.2.4 R&D and Investment
    • 4.2.5 Production and Sales
    • 4.2.6 Vaccine Business
    • 4.2.7 Development Strategy
  • 4.3 Hualan Biological Engineering Inc.
    • 4.3.1 Profile
    • 4.3.2 Operation
    • 4.3.3 Revenue Structure
    • 4.3.4 R&D
    • 4.3.5 Vaccine Business
    • 4.3.6 Development Strategy
  • 4.4 Chongqing Zhifei Biological Products Co., Ltd.
    • 4.4.1 Profile
    • 4.4.2 Operation
    • 4.4.3 Revenue Structure
    • 4.4.4 Gross Margin
    • 4.4.5 R&D
    • 4.4.6 Development Dynamics
    • 4.4.7 Development Strategy
  • 4.5 Walvax Biotechnology Co, Ltd.
    • 4.5.1 Profile
    • 4.5.2 Operation
    • 4.5.3 Revenue Structure
    • 4.5.4 Gross Margin
    • 4.5.5 R&D
    • 4.5.6 Vaccine Business
    • 4.5.7 Development Strategy
  • 4.6 Liaoning Cheng Da Co., Ltd.
    • 4.6.1 Profile
    • 4.6.2 Operation
    • 4.6.3 Revenue Structure
    • 4.6.4 Gross Margin
    • 4.6.5 Major Customers
    • 4.6.6 R&D
    • 4.6.7 Development Strategy
  • 4.7 Shenzhen Kangtai Biological Products Co., Ltd.
    • 4.7.1 Profile
    • 4.7.2 Operation
    • 4.7.3 Revenue Structure
    • 4.7.4 Gross Margin
    • 4.7.5 R&D
    • 4.7.6 Development Strategy
  • 4.8 Changsheng Bio-Technology Co., Ltd.
    • 4.8.1 Profile
    • 4.8.2 Operation
    • 4.8.3 Revenue Structure
    • 4.8.4 R&D
    • 4.8.5 Development Dynamics
  • 4.9 Olymvax Biopharmaceuticals Inc.
    • 4.9.1 Profile
    • 4.9.2 Operation
    • 4.9.3 Revenue Structure
    • 4.9.4 Gross Margin
    • 4.9.5 R&D
    • 4.9.6 Vaccine Business
    • 4.9.7 Development Strategy
  • 4.10 Sinovac Biotech Ltd.
    • 4.10.1 Profile
    • 4.10.2 Operation
    • 4.10.3 Revenue Structure
    • 4.10.4 Sinovac Biotech (Beijing)
  • 4.11 Changchun BCHT Biotechnology Co. Ltd.
    • 4.11.1 Profile
    • 4.11.2 Operation
    • 4.11.3 Development Dynamics
  • 4.12 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
    • 4.12.1 Profile
    • 4.12.2 Operation
  • 4.13 Tibet Amy Biotech & Vaccine Group Co., Ltd.
    • 4.13.1 Profile
    • 4.13.2 Vaccine Business
    • 4.13.3 Amy ConVac Biopharmaceutical (Jiangsu) Co., Ltd.
    • 4.13.4 Aimei Hissen Vaccine (Dalian) Co., Ltd.
    • 4.13.5 Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd.
  • 4.14 NCPC GeneTech Biotechnology Development Co., Ltd.
    • 4.14.1 Profile
    • 4.14.2 Operation
  • 4.15 Dalian Aleph Biomedical Co., Ltd.
    • 4.15.1 Profile
    • 4.15.2 Vaccine Business
  • 4.16 Beijing Minhai Biotechnology Co., Ltd.
    • 4.16.1 Profile
    • 4.16.2 Operation
  • 4.17 CanSino Biologics
    • 4.17.1 Profile
    • 4.17.2 Operation
    • 4.17.3 R&D and Investment
    • 4.17.4 Development Strategy
  • 4.18 Chengdu Kanghua Biological Products Co., Ltd.
    • 4.18.1 Profile
    • 4.18.2 Operation
    • 4.18.3 Revenue Structure
    • 4.18.4 Gross Margin
    • 4.18.5 R&D
  • 4.19 Other Enterprises
    • 4.19.1 Shenzhen Sanofi Pasteur Biological Products Co., Ltd.
    • 4.19.2 Guangzhou Nuocheng Biological Products

5. Summary and Forecast

  • 5.1 Summary
  • 5.2 Development Trends
    • 5.2.1 Human Vaccine Industry is Increasingly Concentrated
    • 5.2.2 Two-child Policy is in Favor of Human Vaccine Industry Growth
    • 5.2.3 Faster Aging of Population Boosts Human Vaccine Industry
    • 5.2.4 Local Companies Invest More Heavily in Research and Development of Vaccine Products Which are Becoming More Various
    • 5.2.5 Demand for Extra EPI Vaccines Is Growing
    • 5.2.6 Coronavirus Vaccines Will Boom

Selected Charts

  • Classification of Vaccines
  • Vaccine Industry Chain
  • Global Human Vaccine Market Size, 2010-2020
  • Global Human Vaccine Market Size, 2019-2026E
  • Top 15 Vaccine Products Worldwide by Sales, 2019
  • Global Vaccine Market Share, 2019
  • R&D Pipelines of Global Top 4 Vaccine Giants
  • Main Mergers & Acquisitions in the Vaccine Industry Worldwide, 2005-2020
  • Revenue of Major Global Vaccine Companies, 2011-2019
  • Related Policies in China Human Vaccine Industry, 2006-2020
  • Gross Industrial Output Value of China Biopharmaceutical Industry, 2008-2020
  • Gross Industrial Output Value of China Biopharmaceutical Industry, 2019-2026E
  • Immunization Procedures (2020) of National EPI Vaccine for Children
  • EPI Human Vaccine Varieties in China
  • Top10 Human Vaccines by Lot Release Volume in China, 2019-2020
  • Lot Release Volume of Human Vaccine in China, 2013-2020
  • Main Human Vaccine Varieties and Producers Granted Permit for Lot Release in China, 2020H1
  • Timeline for Vaccine Blockbusters on Market in China
  • China Human Vaccine Market Size, 2010-2020
  • China's Human Vaccine Import Volume and Value by Country, Jun.-May., 2020
  • Top 10 Countries/Regions of China Human Vaccine Export, Jun.-May., 2020
  • Export Volume and Value of Human Vaccine in China, 2010-2020
  • Average Unit Export/Import Price of Human Vaccine in China, 2010-2020
  • Lot Release Volume Breakdown of Human Vaccines in China by Nature of Enterprise, 2019
  • Stratified Comparison between Local Vaccine Companies in China
  • Human Vaccine Lot Release Volume of Major Vaccine Enterprises in China, 2015-2020
  • Lot Release Volume Breakdown of Human Vaccines in China by Nature of Enterprise, 2020H1
  • Lot Release Volume of Human Vaccines in China by Enterprise, 2019
  • Lot Release Volume of Human Vaccines in China by Enterprise, 2020H1
  • Vaccine Revenue of Major Human Vaccine Enterprises in China, 2013-2019
  • Lot Release Volume of Major Hepatitis B Vaccine Companies in China, 2013-2020
  • Hepatitis B Morbidity and Mortality in China, 2013-2019
  • Lot Release Volume of Hepatitis B Vaccine in China, 2013-2020
  • Lot Release Volume of Hepatitis B Vaccine in China by Dosage Form, 2013-2020
  • Share of Major Hepatitis B Vaccine Companies by Lot Release Volume in China, 2013-2020
  • Meningitis Morbidity and Mortality in China, 2013-2019
  • Meningococcal Vaccines Lot Release Volume in China, 2013-2020
  • Meningococcal Vaccines Lot Release Volume in China by Type, 2013-2020
  • Lot Release Volume of Major Meningococcal Vaccines Companies in China, 2013-2020
  • Share of Major Meningococcal Vaccines Companies by Lot Release Volume in China, 2013-2020
  • R&D Status of Meningococcal Conjugate Vaccine in China
  • Hepatitis A Morbidity and Mortality in China, 2013-2019
  • Lot Release Volume of Hepatitis A Vaccine in China, 2013-2020
  • Lot Release Volume of Major Hepatitis A Vaccine Companies in China, 2013-2020
  • Share of Major Hepatitis A Vaccine Companies by Lot Release Volume in China, 2013-2020
  • Influenza Morbidity and Mortality in China, 2013-2019
  • H7N9 Influenza Morbidity and Mortality in China, 2013-2019
  • Lot Release Volume of Influenza Vaccine in China, 2013-2020
  • Lot Release Volume of Major Influenza Vaccine Companies in China, 2013-2019
  • Share of Major Influenza Vaccine Companies by Lot Release Volume in China, 2013-2019
  • Influenza Outbreak in China, 2014-2020
  • Free Influenza Vaccination for Targeted Groups in Some Places of China
  • R&D of Quadrivalent Influenza Vaccine in China
  • Lot Release Volume of Hib Vaccine in China, 2013-2020
  • Lot Release Volume of Major Hib Vaccine Companies in China, 2013-2020
  • Share of Major Hib Vaccine Companies by Lot Release Volume in China, 2013-2020
  • Rabies Morbidity and Mortality in China, 2013-2019
  • Lot Release Volume of Human Rabies Vaccine in China, 2013-2020
  • Lot Release Volume of Major Human Rabies Vaccine Companies in China, 2013-2020
  • Share of Major Human Rabies Vaccine Companies by Lot Release Volume in China, 2013-2020
  • Types of Rabies Vaccines for Human Use Now in China
  • Progress in R&D of Human Rabies Vaccine (Human Diploid Cell) in China
  • Lot Release Volume of Varicella Vaccine in China, 2013-2020
  • Lot Release Volume of Major Varicella Vaccine Companies in China, 2013-2020
  • Share of Major Varicella Vaccine Companies by Lot Release Volume in China, 2013-2020
  • R&D of Varicella Vaccine in China
  • Vaccination Rate for Varicella in China and the Developed Countries
  • Lot Release Volume of Pneumococcal Vaccines in China, 2013-2020
  • Lot Release Volume of Major Pneumococcal Vaccines Companies in China, 2013-2020
  • Share of Major Pneumococcal Vaccine Companies by Lot Release Volume in China, 2013-2020
  • Global Revenue from 13-valent Pneumococcal Vaccines, 2012-2019
  • Key Chinese Companies' Progress in R&D of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
  • Key Chinese Companies Progress in R&D of 23-valent Pneumococcal Vaccine
  • Distribution Graph of National Immunization Program where 13-valent Pneumococcal Vaccine Gets Enlisted Worldwide, 2019
  • Pertussis Morbidity and Mortality in China, 2012-2019
  • Neonatal Tetanus Morbidity and Mortality in China, 2012-2019
  • Lot Release Volume of DTP Vaccine in China, 2013-2020
  • Lot Release Volume of Major DPT Vaccine Companies in China, 2013-2020
  • Share of Major DTP Vaccine Companies by Lot Release Volume in China, 2013-2020
  • DTcP Vaccines Launched or Being Developed in China
  • Lot Release Volume of Poliomyelitis Vaccine Companies in China, 2013-2020
  • Share of Major Poliomyelitis Vaccine Companies by Lot Release Volume in China, 2013-2020
  • R&D of Poliomyelitis Vaccine in China
  • Lot Release Volume of Poliomyelitis Vaccine in China, 2013-2020
  • Hepatitis E Morbidity and Mortality in China, 2012-2019
  • Lot Release Volume of Hepatitis E Vaccine in China, 2013-2020
  • Lot Release Volume of Major Hepatitis E Vaccine Companies in China, 2013-2020
  • Global Incidence of Cervical Cancer
  • Correlation between HPV Virus and Various Diseases
  • HPV Vaccine Products Worldwide
  • Lot Release Volume of HPV Vaccine in China, 2017-2020
  • Global HPV Vaccine Revenue (by Product), 2006-2019
  • Lot Release Volume of HPV Vaccine in China by Enterprise, 2017-2020
  • Major HPV Vaccine Developers in China and Their Progress
  • List of Countries Bringing HPV Vaccine into Vaccination Program (Those in Green Having Done This)
  • Lot Release Volume of Enterovirus 71 Inactivated Vaccines in China, 2016-2020
  • Product Comparison between Major Chinese Producers of Enterovirus 71 (EV71) Inactivated Vaccine
  • Lot Release Volume of Enterovirus 71 Inactivated Vaccines (by Enterprise) in China, 2016-2020
  • Shares for Lot Release Volume of Enterovirus 71 Inactivated Vaccines (by Enterprise) in China, 2016-2020
  • Specifications and Place of Origin of China National Biotech Group's Main Vaccine Products
  • Vaccine Varieties of Chengdu Institute of Biological Products
  • Vaccine Varieties of Shanghai Institute of Biological Products
  • Revenue and Net Income of Beijing Wantai Biological Pharmacy Enterprise, 2016-2020
  • Revenue of Beijing Wantai Biological Pharmacy Enterprise by Product, 2016-2019
  • Revenue of Beijing Wantai Biological Pharmacy Enterprise by Region, 2016-2019
  • Beijing Wantai Biological Pharmacy Enterprise's R&D Costs and % of Total Revenue, 2016-2020
  • Wantai's Vaccines under Development, as of April 2020
  • Wantai's Representative Innovative Vaccines
  • Beijing Wantai Biological Pharmacy Enterprise's Projects with Funds Raised by IPO
  • Output and Sales of Beijing Wantai Biological Pharmacy Enterprise by Product, 2016-2019
  • Hepatitis E Vaccine Capacity, Output and Capacity Utilization of Beijing Wantai Biological Pharmacy Enterprise, 2016-2019
  • Hepatitis E Vaccine Revenue, Sales Volume and Average Price of Beijing Wantai Biological Pharmacy Enterprise, 2016-2019
  • Gross Margin of Hepatitis E Vaccine of Beijing Wantai Biological Pharmacy Enterprise, 2016-2019
  • Revenue and Net Income of Hualan Biological Engineering, 2013-2020
  • Revenue Breakdown of Hualan Biological Engineering by Sector, 2013-2019
  • Revenue Structure of Hualan Biological Engineering by Sector, 2013-2019
  • R&D Costs and % of Total Revenue of Hualan Biological Engineering, 2013-2020
  • Vaccine Output & Sales Volume, Inventory of Hualan Biological Engineering, 2013-2019
  • Vaccine Revenue and Percentage of Hualan Biological Engineering, 2013-2019
  • Vaccine Gross Margin of Hualan Biological Engineering, 2013-2019
  • Main Products Chongqing Zhifei Biological Products is Selling or Promoting according to Agreements, and Their Purposes
  • Revenue and Net Income of Zhifei Biological, 2012-2020
  • Revenue Breakdown of Zhifei Biological by Product, 2014-2019
  • Lot Release Volume Breakdown of Zhifei Biological by Product, 2014-2019
  • Revenue Breakdown of Zhifei Biological by Region, 2015-2019
  • Gross Margin of Zhifei Biological by Product, 2013-2019
  • R&D Costs and % of Total Revenue of Zhifei Biological, 2012-2020
  • Projects under Registration Process of Zhifei Biological, as of 2019
  • Progress of Preclinical Projects of Zhifei Biological by 2019
  • R&d Projects with Phased Achievements in 2019
  • Revenue and Net Income of Walvax Biotechnology, 2013-2020
  • Revenue Breakdown of Walvax Biotechnology by Product, 2015-2019
  • Revenue Breakdown of Walvax Biotechnology by Region, 2015-2019
  • Gross Margin of Own Vaccine of Walvax Biotechnology, 2013-2019
  • R&D Costs and % of Total Revenue of Walvax Biotechnology, 2013-2020
  • Progress of Walvax Biotechnology's Projects with Raised Fund, as of 2020Q1
  • Product Registration and Application Progress of Walvax Biotechnology, by 2020Q1
  • Progress of Products under Registration Declaration of Walvax Biotechnology, as of 2019
  • Walvax Biotechnology's Timeline of R&D and GMP Application of 13-valent Pneumococcal Vaccine
  • Output & Sales Volume, Inventory of Walvax Biotechnology, 2014-2019
  • Lot Release Volume of Walvax Biotechnology, 2015-2020
  • Revenue and Net Income of Liaoning Chengda, 2013-2020
  • Revenue Breakdown of Liaoning Chengda by Product, 2013-2019
  • Revenue Structure of Liaoning Chengda by Product, 2013-2019
  • Gross Margin of Liaoning Chengda, 2013-2019
  • Liaoning Chengda's Revenue from Top5 Customers and % of Total Revenue, 2015-2019
  • R&D Costs and % of Total Revenue of Liaoning Chengda, 2014-2020
  • Main Products and Their Purposes of Shenzhen Kangtai Biological Products
  • Capacity, Output & Sales Volume of Shenzhen Kangtai Biological Products, 2013-2017
  • Revenue and Net Income of Kangtai Biological, 2013-2020
  • Revenue Breakdown of Kangtai Biological by Product, 2015-2019
  • Lot Release Volume and Percentage of Kangtai Biological, 2015-2019
  • Revenue Breakdown of Shenzhen Kangtai Biological Products by Region, 2015-2019
  • Gross Margin of Shenzhen Kangtai Biological Products, 2013-2020
  • R&D Costs and % of Total Revenue of Kangtai Biological, 2013-2020
  • Progress of Ongoing Research Projects of Kangtai Biological, as of 2019
  • Major Non-equity Investments by Shenzhen Kangtai Biological Products, as of 2019
  • Revenue and Net Income of Changsheng Bio-technology, 2014-2018
  • Revenue Breakdown of Changsheng Bio-technology by Product, 2014-2018
  • Revenue Structure of Changsheng Bio-technology by Product, 2014-2018
  • Output & Sales Volume, Inventory of Changsheng Bio-technology, 2014-2018
  • Progress of Ongoing Projects of Changsheng Bio-technology as of the end of 2017
  • R&D Costs and % of Total Revenue of Changsheng Bio-technology, 2014-2017
  • Development Course of Olymvax Biopharmaceuticals
  • Revenue and Net Income of Olymvax Biopharmaceuticals, 2017-2020
  • Revenue of Olymvax Biopharmaceuticals by Region, 2017-2019
  • Revenue Breakdown of Olymvax Biopharmaceuticals by Sector, 2017-2019
  • Gross Margin of Olymvax Biopharmaceuticals, 2017-2020
  • Olymvax Biopharmaceuticals's R&D Costs and % of Total Revenue, 2017-2019
  • Tetanus Vaccine (Adsorbed) Capacity, Output and Capacity Utilization of Olymvax Biopharmaceuticals, 2017-2019
  • Main Products of Sinovac Biotech
  • Revenue and Net Income of Sinovac Biotech, 2013-2020
  • Revenue Breakdown of Sinovac Biotech by Product, 2013-2020
  • Equity Structure of Sinovac Biotech
  • Financial Indices of Sinovac Biotech, 2015-2019
  • Financial Indices of Changchun BCHT Biotechnology, 2014-2019
  • Vaccine Products of Zhejiang Tianyuan Bio-Pharmaceutical
  • Equity Structure of Amy Biotech
  • Major Vaccine Companies of Amy Biotch
  • Lot Release Volume of Human Vaccines of Amy Biotch, 2018-2019
  • Financial Indices of NCPC GeneTech Biotechnology Development, 2014-2019
  • Equity Structure of Dalian Aleph Biomedical
  • Development Goals of Dalian Aleph Biomedical
  • Financial Indices of Beijing Minhai Biotechnology, 2015-2020
  • Milestones of CanSino
  • Consolidated Income of CanSino Biologics, 2016-2019
  • R&D Cost of CanSino, 2016-2019
  • Vaccine Pipelines of CanSino under Research
  • Revenue and Net Income of Kanghua Biological, 2015-2020
  • Revenue of Kanghua Biological by Product, 2015-2020
  • Output, Sales Volume and Sales-output Ratio of Kanghua Biological,2015-2019
  • Capacity and Capacity Utilization of Kanghua Biological,2015-2019
  • Gross Margin of Kanghua Biological, 2015-2020
  • R&D cost of Kanghua Biological, 2015-2020
  • R&D cost of Kanghua Biological by Project, 2015-2019
  • IPO Investment Projects of Kanghua Biological, 2019
  • China's Vaccine Market Size, 2019-2026E
  • Number of Newborns in China, 2015-2026E
  • China's Population Aged over 60 and % of Total Population, 2009-2025
  • R&D Investment of Major Vaccine Companies in China, 2013-2019
  • Main Vaccine Products Being Researched by Companies in China and Their Progress
  • Comparison between EPI Vaccine and Extra EPI Vaccine in China
  • Main Chinese Vaccine Companies' Efforts in Extra EPI Vaccines
  • Extra EPI Vaccines Paid by Medical Insurance and Financial Subsidy Policies in China by Region
  • COVID-19 Pandemic Map as of July 21, 2020
  • Some Mainstream Approaches to Coronavirus Vaccine R&D
  • Progress in Global R&D of Coronavirus Vaccines
  • Comparison of Coronavirus Vaccines between CanSino Bilogics and Moderna